SEATTLE, May 05, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in two upcoming investor conferences. Presentation details are as follows:
BofA Securities 2022 Healthcare Conference – Las Vegas, NV
- Fireside chat
- Wednesday May 11, 2022, at 1:20 p.m. Pacific
H.C. Wainwright Global Investment Conference – Miami, FL
- Company presentation
- Wednesday, May 25, 2022, at 12:30 p.m. Eastern
The webcast presentations can be accessed from the investors section of the Neoleukin website at http://investor.neoleukin.com/events. Archived replays will also be available on the company website for at least 30 days following the event.
About Neoleukin Therapeutics, Inc.
Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.
Source: Neoleukin Therapeutics, Inc.